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Abstract
Background—Few options exist for patients with localized esophageal cancer ineligible for
conventional therapies. Endoscopic spray cryotherapy with low-pressure liquid nitrogen has
demonstrated efficacy in this setting in early studies.
Objective—To assess the safety and efficacy of cryotherapy in esophageal carcinoma.
Design—Multicenter, retrospective cohort study.
Setting—Ten academic and community medical centers between 2006 and 2009.
Patients—Subjects with esophageal carcinoma in whom conventional therapy failed and those
who refused or were ineligible for conventional therapy.
Interventions—Cryotherapy with follow-up biopsies. Treatment was complete when tumor
eradication was confirmed by biopsy or when treatment was halted because of tumor progression,
patient preference, or comorbid condition.
Main Outcome Measurements—Complete eradication of luminal cancer and adverse events.
Results—Seventy-nine subjects (median age 76 years, 81% male, 94% with adenocarcinoma)
were treated. Tumor stage included T1-60, T2-16, and T3/4-3. Mean tumor length was 4.0 cm
(range 1–15 cm). Previous treatment including endoscopic resection, photodynamic therapy,
esophagectomy, chemotherapy, and radiation therapy failed in 53 subjects (67%). Forty-nine
completed treatment. Complete response of intraluminal disease was seen in 31 of 49 subjects
(61.2%), including 18 of 24 (75%) with mucosal cancer. Mean (standard deviation) length of
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follow-up after treatment was 10.6 (8.4) months overall and 11.5 (2.8) months for T1 disease. No
serious adverse events were reported. Benign stricture developed in 10 (13%), with esophageal
narrowing from previous endoscopic resection, radiotherapy, or photodynamic therapy noted in 9
of 10 subjects.
Limitations—Retrospective study design, short follow-up.
Conclusions—Spray cryotherapy is safe and well tolerated for esophageal cancer. Short-term
results suggest that it is effective in those who could not receive conventional treatment, especially
for those with mucosal cancer.
Esophagectomy traditionally has been considered standard therapy for early-stage
esophageal cancer. Because of age or coexisting medical conditions, many patients are poor
candidates for this procedure, and alternative treatments have been sought. Endoscopic
management, particularly endoscopic resection, has been studied extensively and its
effectiveness demonstrated in selected patients.1 Complete endoscopic resection of tumors
covering larger areas is problematic, and repeat resection or ablation is necessary for cancer
or dysplasia involving cautery margins to minimize the risk of relapse.2 Endoscopic
resection is also difficult in the presence of an ulcerating tumor or in the setting of
significant fibrosis or stenosis. In more advanced disease, with extension through the
esophageal wall or with lymph node metastasis, initial treatment commonly consists of
concurrent chemotherapy and external beam radiotherapy. Residual disease in the esophagus
after chemotherapy, surgery, and/or radiotherapy in the patient not suitable for
esophagectomy presents another management challenge. A significant need exists for
alternative approaches in these patients.
Endoscopic spray cryotherapy using low-pressure liquid nitrogen was first reported by
Johnston et al3 in the treatment of Barrett's esophagus. After their initial report, this group
also described a patient with recurrent squamous cell esophageal cancer successfully treated
with this modality.4 Recent single-site studies have demonstrated the safety and efficacy of
cryotherapy in treating dysplasia and cancer of the esophagus.5,6 In this study, we describe
the results of a multicenter study evaluating spray cryotherapy for the treatment of
esophageal cancer not amenable to more traditional methods.
METHODS
Subjects
Patients treated with low-pressure liquid nitrogen endoscopic spray cryotherapy (CryoSpray
Ablation System, CSA Medical, Baltimore, Md) at 10 institutions were enrolled. Site data
were collected retrospectively. Eligible patients included those with esophageal carcinoma,
either adenocarcinoma or squamous cell carcinoma, who received 1 or more treatments with
endoscopic spray cryotherapy with either curative or palliative intent. Tumors were staged
by EUS and/or endoscopic resection. The goal of treatment was elimination of all
endoscopically evident tumor. All patients with mucosal carcinoma either were deemed
inoperable based on medical conditions or refused esophagectomy. Patients with more
invasive cancer either were deemed inoperable based on medical conditions or refused
esophagectomy, had refused or were ineligible for systemic therapy including chemotherapy
and radiation therapy after oncology evaluation, or systemic therapy including
chemotherapy and radiation therapy had failed. Patients who previously had undergone
endoscopic resection were confirmed to have residual cancer for inclusion in the study.
Efficacy, but not full safety, data on 7 patients in this cohort were previously reported.5,6
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Informed consent was obtained from all patients. Patients were prepared for EGD in the
usual fashion with an overnight fast. Sips of clear liquids with required medications were
allowed up to 2 hours before the procedure. Moderate sedation with intravenous meperidine
or fentanyl and midazolam or monitored anesthesia care with propofol was administered
based on physician preference. EGD by using a standard upper endoscope was performed
with monitoring of pulse oximetry and blood pressure. A 16F modified orogastric tube
(cryodecompression tube) was passed over a guidewire through the mouth into the stomach
before initiation of cryospray. This tube contains decompression ports spanning the distal 12
inches to allow gas venting of both the stomach and the esophagus during treatment. The
tube was connected to continuous suction throughout the cryotherapy procedure.
Spray cryotherapy was performed with low-pressure liquid nitrogen (<5 psi) with energy
delivery of 25 W. After passing the cryotherapy catheter through the working channel of the
endoscope, liquid nitrogen was sprayed through the catheter, forming a white frost and
freezing the adjacent mucosa (Fig. 1). Each mucosal site typically was frozen for 20 seconds
for 3 cycles, with at least 45 seconds between freezes to allow complete tissue thawing, as
verified by a return to baseline color of the tissue and complete disappearance of ice crystals
after reperfusion. In situations in which the decompression tube blocked the targeted
treatment site, the endoscope tip was used to gently reposition the tube out of the way,
allowing appropriate treatment. One to 5 sites in the esophagus were typically treated at each
session. Patients were monitored post-procedure in the usual manner and were discharged
the same day. Procedures were repeated every 4 to 6 weeks. Treatment was deemed
complete by the investigator after complete local tumor eradication as determined by the
endoscopic appearance (Fig. 2) with endoscopic biopsy confirmation of the lack of residual
disease (complete response) or when treatment was halted because of tumor progression,
patient preference, or a comorbid condition precluding further endoscopy (treatment failure).
In some cases, cryotherapy was continued after tumor ablation to achieve eradication of
dysplasia or residual intestinal metaplasia. Follow-up endoscopy with esophageal biopsy at
the treatment site was performed every 3 to 6 months after ablation was complete.
Data collection and analysis
The data for the following variables were collected for each subject: age, sex, ethnicity,
histology, tumor T and N stages, previous or concurrent treatments, adverse events, number
of treatment sessions, and results of cryotherapy. The cohort was divided into 2 groups for
analysis. All subjects and treatments were assessed for the safety analysis. The outcomes
assessed for the safety analysis included strictures, bleeding, chest pain requiring narcotics,
hemorrhage, perforation, and other serious adverse events. The efficacy analysis included
only those subjects who completed treatment (as judged by the treating physician, described
previously). Dropouts and deaths were included in the efficacy analysis as treatment
failures. The primary outcome variable of the efficacy analysis was complete eradication of
all luminal cancer, confirmed by histological examination of biopsy specimens from the
treated area. Secondary outcomes included complete eradication of all intestinal metaplasia.
Mean and standard deviation (SD) or mean and interquartile range (IQR) are reported for
continuous variables. Proportions are reported for categorical variables.
This study was approved by the institutional review board at each site.
RESULTS
Seventy-nine subjects were enrolled at the participating institutions, with 49 of them eligible
for efficacy analysis (Table 1). No patients were lost to follow-up. Median age was 76 years
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(range 51–93 years, IQR 17), 81% were male, and the histology finding was
adenocarcinoma in 94% of patients. The mean (SD) tumor length treated was 4.0 (3.4) cm,
with the longest segment measuring 15 cm. The median number of treatments per subject
was 3 (range 1–25, IQR 3). Tumor stage included T1–60 (76%), T2–16 (20%), and T3/T4–3
(4%). Characteristics were similar between the safety and efficacy cohorts. Fifty-three
(67%) subjects had received previous therapy, and 18 (24%) received concurrent therapy for
their cancer (Table 2). Endoscopic resection was the most common treatment, but other
luminal therapies including photodynamic therapy (PDT), argon plasma coagulation, and
radiofrequency ablation were also used. Systemic therapies included concurrent or
sequential chemotherapy and external beam radiation therapy or either of these modalities
alone. Four subjects who had previously refused surgery ultimately underwent
esophagectomy because cryotherapy failed to eradicate tumor.
Safety analysis
A total of 332 treatments were performed in the 79 enrolled subjects. No serious adverse
events, including perforation and hemorrhage, were reported. Benign stricture was noted in
10 (13%) subjects. All 10 had undergone previous tumor therapy, including endoscopic
resection (5 subjects), external beam radiation therapy (2 subjects), PDT alone (1 subject),
PDT and endoscopic resection (1 subject), and concurrent chemotherapy and external beam
radiation therapy (1 subject). Five subjects received additional endoscopic therapy during or
after cryotherapy was completed, including endoscopic resection (3 subjects), endoscopic
resection and argon plasma coagulation (1 subject), and argon plasma coagulation alone (1
subject). Nine of the 10 subjects were noted to have narrowing of the esophageal lumen
before initiation of cryotherapy. Twenty (27%) subjects reported posttreatment pain
requiring the use of narcotic analgesics.
Efficacy analysis
Forty-nine subjects were available for the efficacy analysis. The remaining 30 subjects were
still receiving cryotherapy treatment at the time of data collection. Overall, 30 (61.2%) of 49
subjects demonstrated a complete response with cryotherapy for luminal disease with mean
(SD) follow-up after treatment of 10.6 (8.4) months (Table 3). In this cohort, T1 tumors
were present in 36 (73.5%) of 49 subjects, and endoscopic remission was seen in 26 (72.2%)
of 36 of all T1 tumors and in 18 (75%) of 24 mucosal (T1a) tumors with mean (SD) follow-
up of 11.5 (2.8) months. The median number of cryotherapy sessions in the complete
response group was 3 (range 1–13, IQR 3) and 3 (range 1–12, IQR 5) in the treatment failure
group. In the complete response group, 63% underwent other treatments before cryotherapy
compared with 68% in the treatment failure group (p = not significant). Final histology after
successful treatment was normal squamous mucosa in 16 (53%) subjects, intestinal
metaplasia in 9 (30%), low-grade dysplasia in 4 (13%), and high-grade dysplasia in 1 (3%).
Concurrent treatments were performed in 8 subjects in this cohort. In the complete response
group, this included endoscopic resection/argon plasma coagulation (1 subject), endoscopic
resection alone (1 subject), and radiofrequency ablation (1 subject). In the treatment failure
group, concurrent treatments included esophagectomy (4 subjects) and argon plasma
coagulation (1 subject). No significant difference was seen between the complete response
and treatment failure groups based on age, tumor length, or number of subjects receiving
previous or concurrent therapy. If subjects who received concurrent therapies are excluded,
27 of 41 subjects (66%) demonstrated a complete response for luminal disease. In this
cohort, T1 tumors were present in 29 (71%), and endoscopic remission was seen in 23 of 29
(79%) of all T1 tumors and in 16 of 19 (84%) of all mucosal (T1a) tumors.
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This study contained a limited number of subjects with T2 and T3 disease. Of the 16
subjects with stage T2, treatment was complete in 10 with 1 to 17 months of follow-up, with
only 3 subjects attaining a complete response. Two subjects with T3 disease were treated in
this study. Both received chemotherapy and radiation before cryotherapy, and one also
underwent esophagectomy before disease recurrence developed. The cryotherapy responder
required 8 treatment sessions at 4- to 6-week intervals, with biopsy 1 month after the last
treatment, demonstrating the absence of luminal cancer. The 4 patients with T2/T3 disease
who completed treatment and were free of luminal disease had follow-up ranging from 2 to
6 months.
Eight subjects died of disease during the study period. T stage in this group included T1–2
(T1a–1, T1b–1), T2–5, and T3–1. All subjects had received previous treatment including
PDT (1 subject), radiation (2 subjects), concurrent chemoradiation (4 subjects), or PDT and
chemoradiation (1 subject). They received 2 to 12 cryotherapy treatments and survived up to
12 months after cryotherapy was halted.
DISCUSSION
Endoscopic management of superficial esophageal cancer is becoming more common
because of the increasing incidence of this disease and the lack of suitability of
esophagectomy in the high-risk population in which it is often diagnosed.7,8 Recent studies
comparing survival rates with endoscopic and surgical management have shown comparable
results in both population-based studies9 and centers with specialized expertise in managing
this condition.7,8 A recent decision analysis suggests that endoscopic management is cost-
effective as well.10
In highly selected patients, endoscopic resection can be curative for superficial cancer.
However, in a recent study, only 100 of 329 patients screened met criteria for low-risk
disease, which justified endoscopic resection. In this select group, treatment was very
successful, with 99 of 100 patients ultimately achieving complete response.1 Complete
endoscopic resection of intestinal metaplasia and superficial adenocarcinoma has
demonstrated high rates of technical success, but development of strictures limits
applicability in longer esophageal segments.11 Porfimer sodium PDT with or without
previous endoscopic resection has been used with mixed results in this setting, with
remission of cancer seen in 20 of 24 (83%) using endoscopic resection followed by PDT,12
but in only 4 of 9 (44%) subjects using PDT alone.13 Endoscopic resection followed by
radiofrequency ablation is effective for focal cancers,14 but the superficial depth of injury
with radiofrequency ablation makes it unsuitable as a primary cancer treatment.
For more advanced esophageal cancers, conventional therapies include esophagectomy or
concurrent chemo-therapy and external beam radiotherapy (chemoradiation). Although the
success rate for esophagectomy in stage 1 disease is high and the mortality rate lower than
commonly quoted,15 the morbidity and altered quality of life with this surgery have driven
the search for alternative therapies. Concurrent chemoradiation is widely used before
esophagectomy (neoadjuvant therapy) in advanced disease and as definitive therapy in those
deemed to be poor surgical candidates.16 Pathological complete response to therapy is
reported to be as high as 40%,17 with 2-year local control rates between 41% and 57%.18,19
Success has been reported with salvage esophagectomy in those with local persistence or
recurrence, but it is associated with increased mortality and complications, including
anastomotic leak.20
Endoscopic salvage therapies for local control include PDT and endoscopic resection. In one
study, complete response was seen in 8 of 13 patients treated with PDT after definitive
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combined chemoradiation failed, with 6 patients disease free at 12 months.21 Complications
were common in this study, including 1 fatal tracheoesophageal fistula, 1 patient with
mediastinitis, and 3 patients with strictures requiring dilation. In another series, complete
response was seen in 8 of 15 patients (53%) receiving salvage PDT. Complications
developed in 7 of 15 (47%) compared with 8% in those receiving PDT as primary therapy.
These complications included fatal esophageal perforation in 2 subjects and esophageal
stricture requiring dilation in 5 (33.3%).22
In selected patients, endoscopic resection after definitive chemoradiation has been shown to
control local disease. In one study, 16 of 93 patients with residual cancer after
chemoradiation had disease limited to the mucosa/submucosa and underwent salvage
endoscopic resection. Complete response was seen in half, with a 3-year survival rate of
56% compared with 38% in the total group of 93 patients.23 In a similar study, 8 (38%) of
21 patients were alive without disease recurrence, with a 5-year overall survival rate of
49%.24 Endoscopic resection was limited to patients with disease confined to the mucosa
and submucosa and without deep ulceration. No serious adverse events were reported in
either study, although bleeding, stricture, and perforation have been reported in other studies
using this modality in early cancer.11,25
Endoscopic spray cryotherapy with low-pressure liquid nitrogen is a novel method for the
treatment of malignant and premalignant conditions of the esophagus. It is designed to
deliver a high rate of thermal energy transfer via a 7F catheter in a noncontact manner. This
form of cryo-therapy delivers approximately 25 W (joules per second) of energy to the
targeted area, approximating the energy transfer of a laser and many times the energy
transfer associated with cryotherapy using a standard cryotherapy probe.26 This rapid
delivery of thermal energy by using liquid nitrogen at −196°C effectively snap-freezes the
tissue and results in immediate cell death.27 Although the degree of cell death is similar to
those of the heat-related thermal modalities such as radiofrequency ablation and argon
plasma coagulation, spray cryotherapy preserves the underlying tissue architecture and
extracellular matrix, producing a favorable wound response with little evidence of long-term
scarring.28 Spray cryotherapy is currently being used to treat a variety of different disease
processes including glottic and subglottic stenosis,29 malignancy in the pleura,30,31 and
radiation proctitis.32,33
In 2007, Cash et al4 reported the first use of spray cryotherapy in the palliation of recurrent
esophageal squamous cell carcinoma 3 years after definitive chemoradiation. After 2
treatment sessions, the patient remained free of disease at 2-year follow-up. A recent study
evaluating the safety and efficacy of spray cryotherapy included 7 patients with superficial
esophageal cancer, and elimination of cancer in the esophageal lumen was seen in all 7 with
follow-up ranging from 3 to 18 months.6 A recent case series of 31 patients included 5 with
intramucosal carcinoma, with response to therapy seen in 4 of 5 and no cancer recurrence
seen in 3 of 5.5
In this study, we evaluated 79 cryotherapy patients from 10 institutions with esophageal
carcinoma in whom other therapy failed or who refused or were ineligible for any other
therapy. Because of the concern for disease extension beyond the mucosa and the potential
for lymph node metastases, all of these subjects were considered for conventional therapy.
Subjects entered therapy with the express goal of tumor palliation; however, endoscopic
complete response was achieved in 61.2% overall and 75% of mucosal cancers with a mean
follow-up of almost 1 year in the T1 group. These percentages cannot be construed as cure
rates because follow-up was short and because more distant disease could not be excluded
endoscopically and was not excluded systematically in this retrospective study. However,
they are reasonable short-term estimates of the technology's ability to gain local control of
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the disease. The cause of treatment failure in some subjects is unknown but may have been
because of insufficient treatment dose or cellular resistance to freezing. The stricture rate
seen in this study was comparable to that of a previous study.5
Previous treatment with both endoscopic and systemic therapies was common, with
cryotherapy being used successfully as salvage therapy. It is likely that multimodality
therapy will become increasingly common in patients such as these, given the proliferation
of techniques in therapeutic upper endoscopy. Cryotherapy, sometimes in combination with
endoscopic resection, may offer both local control of the most significant disease and
treatment of the underlying field of dysplastic or metaplastic tissue. Cryotherapy may also
be useful in debulking advanced tumors; however, no published data are available for this
indication.
This is the largest reported series on the use of low-pressure liquid nitrogen spray
cryotherapy for the treatment of esophageal cancer. Strengths of this study include a sample
drawn from both the community and academic medical centers, staging with EUS or
endoscopic resection before treatment, and the use of endoscopic biopsy to confirm
remission. Limitations include retrospective design and relatively short follow-up.
In summary, endoscopic spray cryotherapy is a safe and well-tolerated therapy for
esophageal cancer. It was effective in achieving local control of the disease in a significant
majority of subjects and demonstrated response in those with more advanced disease as
well. This success was associated with no serious adverse events and a low overall
complication rate. Future studies with prolonged follow-up will be useful to evaluate the
durability of response.
Acknowledgments
The authors thank Mark Flasar, M.D., M.S. for statistical assistance.
DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: B.D.
Greenwald: Research grant from, consultant for, and advisory committee member of CSA Medical. J.A. Dumot:
Research grant from and advisory committee member of CSA Medical. C.J. Lightdale: Advisory committee
member of CSA Medical. N.J. Shaheen: Research grant from, consultant for, and advisory committee member of
CSA Medical; research grant from BÂRRX Medical Inc; research grant from, consultant for, and speaker for
Proctor & Gamble; research grant from Oncoscope Inc; research grant from and consultant for Takeda
Pharmaceuticals. All other authors disclosed no financial relationships relevant to this publication. CSA Medical
supported this study through a grant for statistical analysis and by assisting in data collection at some sites. CSA
Medical had no role in study design, analysis, interpretation of the data, or in writing the report.
REFERENCES
1. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas
(Barrett's cancer). Gastrointest Endosc. 2007; 65:3–10. [PubMed: 17185072]
2. Mino-Kenudson M, Brugge WR, Puricelli WP, et al. Management of superficial Barrett's
epithelium-related neoplasms by endoscopic mucosal resection: clinicopathologic analysis of 27
cases. Am J Surg Pathol. 2005; 29:680–6. [PubMed: 15832094]
3. Johnston MH, Eastone JA, Horwhat JD, et al. Cryoablation of Barrett's esophagus: a pilot study.
Gastrointest Endosc. 2005; 62:842–8. [PubMed: 16301023]
4. Cash BD, Johnston LR, Johnston MH. Cryospray ablation (CSA) in the palliative treatment of
squamous cell carcinoma of the esophagus. World J Surg Oncol. 2007; 5:34. [PubMed: 17367523]
5. Dumot JA, Vargo JJ 2nd, Falk GW, et al. An open-label, prospective trial of cryospray ablation for
Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients.
Gastrointest Endosc. 2009; 70:635–44. [PubMed: 19559428]
Greenwald et al. Page 7













6. Greenwald BD, Dumot JA, Horwhat JD, et al. Safety, tolerability, and efficacy of endoscopic low-
pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus. 2010; 23:13–19.
[PubMed: 19515183]
7. Prasad GA, Wu TT, Wigle DA, et al. Endoscopic and surgical treatment of mucosal (T1a)
esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology. 2009; 137:815–23. [PubMed:
19524578]
8. Schembre DB, Huang JL, Lin OS, et al. Treatment of Barrett's esophagus with early neoplasia: a
comparison of endoscopic therapy and esophagectomy. Gastrointest Endosc. 2008; 67:595–601.
[PubMed: 18279860]
9. Das A, Singh V, Fleischer DE, et al. A comparison of endoscopic treatment and surgery in early
esophageal cancer: an analysis of surveillance epidemiology and end results data. Am J
Gastroenterol. 2008; 103:1340–5. [PubMed: 18510606]
10. Pohl H, Sonnenberg A, Strobel S, et al. Endoscopic versus surgical therapy for early cancer in
Barrett's esophagus: a decision analysis. Gastrointest Endosc. 2009; 70:623–31. [PubMed:
19394011]
11. Seewald S, Ang TL, Gotoda T, et al. Total endoscopic resection of Barrett esophagus. Endoscopy.
2008; 40:1016–20. [PubMed: 19065485]
12. Pacifico RJ, Wang KK, Wongkeesong LM, et al. Combined endoscopic mucosal resection and
photodynamic therapy versus esophagectomy for management of early adenocarcinoma in
Barrett's esophagus. Clin Gastroenterol Hepatol. 2003; 1:252–7. [PubMed: 15017665]
13. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with
dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc. 2003; 58:183–8.
[PubMed: 12872083]
14. Pouw RE, Gondrie JJ, Sondermeijer CM, et al. Eradication of Barrett esophagus with early
neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg.
2008; 12:1627–36. discussion 36–7. [PubMed: 18704598]
15. Stein HJ, Feith M, Bruecher BL, et al. Early esophageal cancer: pattern of lymphatic spread and
prognostic factors for long-term survival after surgical resection. Ann Surg. 2005; 242:566–73.
discussion 73–5. [PubMed: 16192817]
16. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin
Oncol. 2007; 25:4110–7. [PubMed: 17827461]
17. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer:
CALGB 9781. J Clin Oncol. 2008; 26:1086–92. [PubMed: 18309943]
18. Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with
chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;
25:1160–8. [PubMed: 17401004]
19. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with
locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005; 23:2310–7.
[PubMed: 15800321]
20. Gardner-Thorpe J, Hardwick RH, Dwerryhouse SJ. Salvage oesophagectomy after local failure of
definitive chemoradiotherapy. Br J Surg. 2007; 94:1059–66. [PubMed: 17657720]
21. Yano T, Muto M, Minashi K, et al. Photodynamic therapy as salvage treatment for local failures
after definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc. 2005; 62:31–6.
[PubMed: 15990816]
22. Lecleire S, Di Fiore F, Antonietti M, et al. Nonoperable patients with superficial esophageal cancer
treated by photodynamic therapy after chemoradiotherapy have more severe complications than
patients treated in primary intent. Am J Gastroenterol. 2008; 103:2215–9. [PubMed: 18844614]
23. Hattori S, Muto M, Ohtsu A, et al. EMR as salvage treatment for patients with locoregional failure
of definitive chemoradiotherapy for esophageal cancer. Gastrointest Endosc. 2003; 58:65–70.
[PubMed: 12838223]
24. Yano T, Muto M, Hattori S, et al. Long-term results of salvage endoscopic mucosal resection in
patients with local failure after definitive chemoradiotherapy for esophageal squamous cell
carcinoma. Endoscopy. 2008; 40:717–21. [PubMed: 18773340]
Greenwald et al. Page 8













25. Pech O, May A, Rabenstein T, et al. Endoscopic resection of early oesophageal cancer. Gut. 2007;
56:1625–34. [PubMed: 17938435]
26. [Accessed November 3, 2009] Percutaneous US-guided prostate cryoablation. Available at:
http://www.galil-medical.com/pdfs/Prostate%20Application%20Sheet%20-%20USA
%202007.pdf.
27. Krimsky WS, Broussard JN, Sarkar SA, et al. Bronchoscopic spray cryotherapy: assessment of
safety and depth of airway injury. J Thorac Cardiovasc Surg. Aug 5.2009 Epub ahead of print.
28. Shepherd JP, Dawber RP. Wound healing and scarring after cryosurgery. Cryobiology. 1984;
21:157–69. [PubMed: 6713945]
29. Krimsky WS, Rodrigues M, Sarkar SA, et al. Spray cryotherapy for the treatment of glottic and
subglottic stenosis. Laryngoscope. 2010; 120:473–7. Epub ahead of print. [PubMed: 20058314]
30. Downie GH, Fields E, DeKaratry D. Malignancy of the parietal pleura:novel treatment with spray
cryoablation. Chest. 2009; 136(Suppl):30S-g–31S-g.
31. Downie G, Krimsky W. Response to spray cryotherapy in a patient with adenocarcinoma in the
parietal pleura. Respiration. Dec 23.2009 Epub ahead of print.
32. Battish R, Shah H, Bashir R. Short-term follow-up of cryoablation treatment for radiation proctitis.
Am J Gastroenterol. 2009; 104(Suppl 3):S390.
33. Shaib Y, Hou J. Complete endoscopic healing of radiation proctitis with low pressure cryoablation.
Am J Gastroenterol. 2008; 103(Suppl 1):S230.
Greenwald et al. Page 9














• Effective treatments for localized esophageal cancer in those who fail or are ineligible
for conventional therapies (surgery, radiation, chemotherapy, endoscopic resection) are
limited. In this study, endoscopic spray cryotherapy is effective in eliminating luminal
disease in a majority of patients in short-term follow-up.
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Endoscopic appearance of frozen esophageal mucosa by using spray cryotherapy with liquid
nitrogen.
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Endoscopic images of a patient with persistent luminal cancer after concurrent
chemotherapy and external beam radiation therapy (chemoradiation) for T2N0 esophageal
adenocarcinoma. A, Initial appearance of cancer before chemoradiation. B, One month after
chemoradiation, esophagitis but no cancer is detectable. C, Appearance 5 months after
chemoradiation, with adenocarcinoma and residual intestinal metaplasia present. D, After 3
cryotherapy sessions, residual cancer is no longer visible. Endoscopic biopsy specimens
showed no evidence of cancer. An ink tattoo is visible marking the previous site of the
tumor.
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TABLE 1
Demographics and baseline characteristics
Total Completed treatment
No. subjects 79 49
Sex, no. (%)
 Male 64 (81.0) 41 (88.6)
 Female 15 (19.0) 8 (11.4)
Histology, no. (%)
 Adenocarcinoma 74 (93.7) 46 (95.5)
 Squamous cell carcinoma 5 (6.3) 3 (4.5)
Age, y, median (range, IQR) 76 (51–93, 17) 75 (51–88, 16)
Ethnicity, no. (%)
 White 72 (96.0) 47 (95.9)
 African American 2 (2.7) 2 (4.1)
 Not stated 5 (1.3)
Tumor stage, no, (%)
 T1
  Mucosal 33 (41.8) 24 (49.0)
  Submucosal 23 (29.1) 10 (20.4)
  Not stated 4 (5.1) 2 (4.1)
  Total T1 60 (76.0) 36 (73.5)
 T2 16 (20.3) 10 (20.4)
 T3 2 (2.5) 2 (4.1)
 T4 1 (1.2) 1 (2.0)
Tumor length, mean (SD) 4.0 (3.4) 4.0 (3.1)
Tumor length, cm, range 1–15 1–12
No. treatments, median (range, IQR) 3 (1–25, 3) 3 (1–13, 3)
IQR, Interquartile range; SD, standard deviation.
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TABLE 2
Therapies used in addition to spray cryotherapy
Previous Concurrent
Therapy* No. % No. %
Endoscopic resection 27 42.2 9 45
Concurrent chemotherapy/external beam radiotherapy 12 18.8
Photodynamic therapy 11 17.2
External beam radiotherapy 7 10.9 2 10
Concurrent chemotherapy/external beam radiotherapy, then esophagectomy 2 3.1
Argon plasma coagulation 2 3.1 3 15
Chemotherapy 1 1.6
Esophageal stent 1 1.6
Radiofrequency ablation 1 1.6 2 10
Esophagectomy 4 20
*
Some patients received more than 1 type of therapy. Count is the number of subjects receiving each therapy. The total number of subjects
receiving previous therapy is 53 and the number receiving concurrent therapy is 18.













Greenwald et al. Page 15
TABLE 3
Treatment results by endoscopic tumor status
Complete endoscopic response Persistent tumor
No. % No. %
Total 30 61.2 19 38.8
By tumor stage
 T1
  Mucosal 18 75.0 6 25.0
  Submucosal 6 60.0 4 40.0
  Not stated 2 100.0 0 0.0
  Total T1 26 72.2 10 27.8
 T2 3 30.0 7 70.0
 T3 1 50.0 1 50.0
 T4 0 0.0 100.0
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